Mechanism for Dexamethasone Inhibition of Neutrophil Migration upon Exposure to Lipopolysaccharide in Vitro: Role of Neutrophil Interleukin-8 Release
- 1 October 1999
- journal article
- Published by Springer Nature in Pediatric Research
- Vol. 46 (4) , 406
- https://doi.org/10.1203/00006450-199910000-00008
Abstract
The mechanism by which dexamethasone (DEX) inhibits neutrophil (PMN) recruitment to a site of inflammation, such as the newborn lung with bronchopulmonary dysplasia, is not completely understood. The aim of our study was to determine whether DEX inhibits neutrophil-induced neutrophil recruitment by inhibition of interleukin- (IL) 8 release from PMNs, and if there are developmental differences. PMNs isolated from cord blood (CB) and adults (A) were studied. We first measured the effect of DEX (10−10 to 10−4 M) on PMN migration to an exogenous IL-8 standard (10−8 M) using PMNs of CB (n= 3) and A (n= 3), over 1 h in a chemotaxis chamber. Second, we determined the effect of DEX (0 and 10−10 to 10−6 M) on IL-8 release (immunoasay) from PMNs of CB (n= 7) or A (n= 7) after incubation with lipopolysaccharide (LPS, 1 ng/mL) for 6 and 18 h. Third, the chemoattractant activity of culture media from the second experiment was studied with and without IL-8 antibody. DEX at concentrations of 10−10 to 10−4 M had no direct effect on PMN migration in vitro to an exogenous IL-8 standard. After LPS exposure, IL-8 release was greatly increased for PMNs from CB compared with A. DEX (10−10 to 10−4 M) resulted in a dose-dependent inhibition of IL-8 release from PMNs exposed to LPS for 6 and 18 h incubation. Increased PMN migration activity was only found with media of PMNs of CB with no DEX. At 18 h, media-induced migration activity was decreased if DEX (10−7 M), IL-8 antibody, or DEX (10−7 M) with IL-8 antibody were present during the incubation with LPS: there was an 88, 86, and 101% reduction in migration activity, respectively. We conclude that DEX inhibits PMN-induced PMN migration, predominantly via inhibition of IL-8 release for PMNs of the newborn. We suggest that a 10-fold lowering of the standard DEX dose may effectively reduce lung inflammation in bronchopulmonary dysplasia.Keywords
This publication has 30 references indexed in Scilit:
- A Multicenter Trial of Two Dexamethasone Regimens in Ventilator-Dependent Premature InfantsNew England Journal of Medicine, 1998
- Nuclear Factor-κB — A Pivotal Transcription Factor in Chronic Inflammatory DiseasesNew England Journal of Medicine, 1997
- Failure of early postnatal dexamethasone to prevent chronic lung disease in infants with respiratory distress syndrome.Archives of Disease in Childhood: Fetal & Neonatal, 1996
- Role of elevated plasma soluble ICAM-1 and bronchial lavage fluid IL-8 levels as markers of chronic lung disease in premature infants.Thorax, 1995
- Effect of pulse dexamethasone therapy on the incidence and severity of chronic lung disease in the very low birth weight infantThe Journal of Pediatrics, 1995
- Earlier identification of biliary atresia and hepatobiliary disease: selective screening in the third week of life.Archives of Disease in Childhood, 1995
- Anti-inflammatory actions of steroids: molecular mechanismsTrends in Pharmacological Sciences, 1993
- Effects of dexamethasone on chemotactic activity and inflammatory mediators in tracheobronchial aspirates of preterm infants at risk for chronic lung diseaseThe Journal of Pediatrics, 1993
- Interleukin-8 (IL-8): The Major Neutrophil Chemotactic Factor in the LungExperimental Lung Research, 1991
- Elastase and alpha 1-proteinase inhibitor activity in tracheal aspirates during respiratory distress syndrome. Role of inflammation in the pathogenesis of bronchopulmonary dysplasia.Journal of Clinical Investigation, 1983